Dose+

MVision AI’s Dose+ Receives FDA 510(k) Clearance for Clinical Use in the United States
Helsinki, September 2025 – MVision AI is proud to announce that Dose+, its AI-powered solution for dose prediction and personalised radiotherapy treatment planning, has received…
AI in Prostate Cancer Radiotherapy Planning
Across much of the world, men are living into older age in greater numbers than ever before. With this increase in years comes a different…
MVision AI’s Dose+ Receives Market Approval in Australia
Helsinki, August 2025 — MVision AI announces that Dose+ has received market approval for the Australian market from the Therapeutic Goods Administration (TGA). The product…
Case Study: Evaluating AI Dose Prediction Across Standard and Complex Prostate Cases at NCCC, Newcastle
Overview For many radiotherapy departments, the integration of new technologies must complement rather than replace established planning processes. The Northern Centre for Cancer Care (NCCC)…
MVision AI Announces Dose+: Dose Prediction Software for AI-driven Radiation Therapy Planning
Helsinki, Finland – February 2025 – MVision AI announces the introduction of Dose+, a software medical device designed to assist radiation therapy professionals in treatment…